ESALF News and Press, Eisai Co Ltd From 05/12/21

Eisai (ESALF): FY GAAP EPS of ¥146.90.Revenue of ¥645.94B (-7.1% Y/Y)FY2021 guidance: Revenue of ¥681B; Profit for the year of ¥45BPress Release For further details see: Eisai reports FY results, provides outlook

Under priority review, the FDA has accepted Merck (MRK) and Eisai's (ESALF) applications seeking two new approvals for the combination of Keytruda plus Lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.The first set of applications (sBLA f...

Biogen (BIIB) and Eisai (ESALF) announce results from Phase 2b trial in Alzheimer's Disease ((AD)) in peer-reviewed journal Alzheimer's Research and Therapy.The manuscript describes results from Study 201, a Phase 2b proof-of-concept clinical trial that explored the impact of treatment w...

A survey JP Morgan conducted of 25 U.S. physicians familiar with Alzheimer's disease found there there is a clear need for a drug that provides even a modest level of treatment benefit.Results indicated that the doctors see broad utilization if Eli Lilly's (LLY) donanemab is approved, with 30...

Three doctors who served on the FDA advisory committee that ultimately voted to reject Alzheimer's drug aducanumab from Biogen (BIIB) and Eisai (ESALF) are reiterating the case that the drug should not be approved.G. Caleb Alexander, Scott Emerson, and Aaron S. Kesselheim say "there is n...

Cassava Sciences (SAVA) shares are soaring in morning trading after Maxim analyst Jason McCarthy raised his price target to $80 from $14.That represents more than a 471% increase.McCarthy cited data released earlier this month from a phase 2b study of the oral drug simufilam in Alzheimer's th...

Finding a treatment that can actually slow the progression of Alzheimer's disease has been referred to as the "holy grail" of drug development.The highway of Alzheimer's drug development is littered with failed candidates that have largely targeted the buildup of beta amyloid, a protein in th...

Eisai Co. Ltd. (ESALF) Q3 2021 Earnings Conference Call February 03, 2021 02:30 AM ET Company Participants Ryohei Yanagi - EVP & CFO Ivan Cheung - SVP & President of Neurology Business Group Takashi Owa - Chief Medicine Creation Officer & Chief Discovery Officer Oncology Terushige...

Morgan Stanley sees the decision by the FDA to extend the review period for aducanumab as a positive for ‘LLY Alzheimer's perception.’Today Biogen ([[BIIB]] +5.6%) and Eisai's ([[ESALF]]) said that the FDA has extended the review period by three months for Biologics Li...

Today, Biogen ([[BIIB]] +10.1%) and Eisai's ([[ESALF]]) announced that FDA has extended the review period for aducanumab by three months, sending the Biogen shares 10% higher in premarket trading.In a note to clients, the analysts at Stifel comment that with the extension of the review period...